Allos Therapeutics Inc: All Recent News

• All recent news
• Earnings news

Market Report -- Short Stories (ALTH) 11/24/2009

Allos Therapeutics initiated with a Buy at ThinkEquity . ThinkEquity initiates ALTH with a Buy based upon their belief that the commercial potential for the newly-approved Folotyn in PTCL is... Briefing.com

Market Report -- In Play (ALTH) 11/24/2009

Allos Therapeutics initiated with a Buy at ThinkEquity ThinkEquity initiates ALTH with a Buy based upon their belief that the commercial potential for the newly-approved Folotyn in PTCL is... Briefing.com

Healthcare Stocks: Safe and Speculative 11/23/2009

NEW YORK (TheStreet) -- Allos Therapeutics is the best speculative bet in the sector. Watch this video for the safest and biggest growth stock to add to your portfolio. At TheStreet.com

A Big Upgrade for Allos Therapeutics 11/23/2009

This bullish call comes from more than just one analyst. At Motley Fool

A Big Upgrade for Allos Therapeutics 11/23/2009

This bullish call comes from more than just one analyst. Motley Fool

Jim Cramer's Portfolios of the Week 11/20/2009

Here's what Cramer's been talking about lately. At TheStreet.com

Cramer's 'Stop Trading!': Bristol-Myers 11/16/2009

Jim Cramer discusses Intel, Boeing, Bristol-Myers and more. At TheStreet.com

Stock Smackdown: Cramer vs. CAPS 11/16/2009

A showdown over who knows stocks better. At Motley Fool

Allos Therapeutics Announces New Data on FOLOTYN™ to be... 11/11/2009

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American... Business Wire

Allos Therapeutics to Present at Upcoming Conferences in November 11/10/2009

Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that management will... Business Wire

The Next Million-Dollar Penny Stock 11/10/2009

Picking up pennies can make you millions. At Motley Fool

Allos Therapeutics Reports Third Quarter 2009 Financial Results 11/3/2009

Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported results for the third quarter of 2009. For the three months ended September 30, 2009, the Company reported a net loss of $18.7 million, or... Business Wire

Shire names David Stout to board 11/2/2009

NEW YORK (AP) - Shire PLC said Monday it named David Stout, former president of pharmaceutical operations at GlaxoSmithKline, to the drug developer's board of directors. Associated Press

Allos Therapeutics to Report Third Quarter 2009 Results on... 10/26/2009

Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that Company management... Business Wire

Allos Therapeutics Announces Closing of Public Offering 10/13/2009

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the closing of its previously announced underwritten public offering of 14,000,000 shares of newly issued common stock at a public offering... Business Wire

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status